Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico

72 Páginas.

Autores:: Rosero Revelo, Ricardo Javier
Rueda Sánchez, Juan Camilo

Tipo de recurso:

Fecha de publicación:: 2013

Institución:: Universidad de la Sabana

Repositorio:: Repositorio Universidad de la Sabana

Idioma:: spa

id	REPOUSABA2_74e924a7cc780e6fda025e2e5889309d
oai_identifier_str	oai:intellectum.unisabana.edu.co:10818/8179
network_acronym_str	REPOUSABA2
network_name_str	Repositorio Universidad de la Sabana
repository_id_str
dc.title.es_CO.fl_str_mv	Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico
title	Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico
spellingShingle	Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico Lupus eritematoso sistémico Citocinas Nefritis
title_short	Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico
title_full	Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico
title_fullStr	Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico
title_full_unstemmed	Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico
title_sort	Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico
dc.creator.fl_str_mv	Rosero Revelo, Ricardo Javier Rueda Sánchez, Juan Camilo
dc.contributor.advisor.none.fl_str_mv	De Zubiría, Alberto Santander, Paola
dc.contributor.author.none.fl_str_mv	Rosero Revelo, Ricardo Javier Rueda Sánchez, Juan Camilo
dc.subject.es_CO.fl_str_mv	Lupus eritematoso sistémico Citocinas Nefritis
topic	Lupus eritematoso sistémico Citocinas Nefritis
description	72 Páginas.
publishDate	2013
dc.date.accessioned.none.fl_str_mv	2013-07-30T19:56:05Z
dc.date.available.none.fl_str_mv	2013-07-30T19:56:05Z
dc.date.created.none.fl_str_mv	2013
dc.date.issued.none.fl_str_mv	2013-07-30
dc.type.none.fl_str_mv	bachelorThesis
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.local.none.fl_str_mv	Tesis de especialización
dc.type.hasVersion.none.fl_str_mv	publishedVersion
dc.identifier.citation.none.fl_str_mv	Singh S., Saxena R., Lupus nephritis. Am J Med Sci 2009; 337: 451-460. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424. Cervera R., Khamashta MA., Font J., et al. Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. The European Working Party on systemic lupus erithematosus. Medicine (Baltimore) 1993; 72: 113-124 Vlachoyiannopoulos PG., Karassa FB., Karakostas KX., et al. Systemic lupus eruthematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993; 2: 303-312. Wallace DJ., Podell TE., Weiner JM., et al. Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 1982; 72: 209-220. Cooper GS., Parks CG., Treadwell EL., et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002; 11: 161-167. Mavragani CP., Moutsopoulos HM. Lupus nephritis: current issues. Ann Rheum Dis 2003; 62: 795-798 Reveille JD., Bartolucci A., Alarcón GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arhtritis Rheum 1990; 33: 37-48 Bagavant H., Fu SM., Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009; 21: 489-494. Horwitz DA., Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994; 16: 181-200. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85: 303-306. Dean SG., Tyrrell-Price J., Crawley E., et al. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 243-251. Jara LJ., Irigoyen L., Ortiz MJ., et al. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998; 17: 110-114. Foster MH., Kelley VR. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin Nephrol 1999; 19: 173-181. Abbas AK., Lichtman AH., Pillai S. Inmunología celular y molecular. 6ta ed. Barcelona: Elsevier Saunders, 2008. Chan RW., Lai FM., Li EK., et al. Intrarenal cytokine gene expression in lupus Nephritis. Ann Rheum Dis 2007; 66: 886-892 Tucci M., Ciavarella S., Strippoli S., et al. Oversecretion of cytokines and chemokines in lupus nephritis is regulated by intraparenchymal dendritic cells. Ann N. Y. Acad Sci 2009; 1173: 449-457. Akahoshi M., Nakashima H., Tanak Y., et al. Th1/Th2 balnce of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1644-1648. Uhm WS., Na K., Song GW., et al. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003; 42: 935-938. Masutani K., Akahoshi M., Tsuruya K., et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44: 2097-2106. Amit M., Mor A., Weissgarten J., et al. Inactive systemic lupus erytematosus is associated with a normal stimulated Th1/Th2 cytokine secretory pattern. Cytokine 2000; 12: 1405-1408. Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol 2007; 27: 47-58. Betelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235-238. Shimizu S., Sugiyama N., Masutani K., et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL27 receptor (WSX-1). J. Immunol 2005; 175: 7185-7192. Rovin BH., Song H., Birmingham DJ., et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467-473. Rovin BH., Birmingham DJ., Nagaraja HN., et al. Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis 2007; 65: 187-193. Chan RW., Tam LS., Li EK., et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003; 48; 1326-1331. 28. Li Y., Tucci M., Narain S., et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006; 5: 383-388. Appel GB., Silva FG., Pirani CL., et al. Renal involvement in systemic lupus erythematosus: a study of 5 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57: 371- 410. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification or systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725 Bombardier C., Gladman DD., Urowitz MB., et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis study in SLE. Arthritis Rheum. 1992; 35: 630-640. Li Y., Tucci M., Narain S., et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006; 5: 383-388. Gladman DD., Urowitz MB., Kagal A., et al. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 2000; 27: 377-379. Ibañez D., Gladman DD., Urowitz M. Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J. Rheumatol 2007; 34: 336-40. Migliorini P., Anzilotti C., Pratesi F., et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur Cytokine Netw 2010; 21: 264-271. Washburn KK., Zappitelli M., Arikan AA., et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant 2008; 23: 566-572. Tucci M., Lombardi L., Richards HB., et al. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Inmunol 2008; 154: 247-254.
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/10818/8179
dc.identifier.local.none.fl_str_mv	254670 TE05960
identifier_str_mv	Singh S., Saxena R., Lupus nephritis. Am J Med Sci 2009; 337: 451-460. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424. Cervera R., Khamashta MA., Font J., et al. Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. The European Working Party on systemic lupus erithematosus. Medicine (Baltimore) 1993; 72: 113-124 Vlachoyiannopoulos PG., Karassa FB., Karakostas KX., et al. Systemic lupus eruthematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993; 2: 303-312. Wallace DJ., Podell TE., Weiner JM., et al. Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 1982; 72: 209-220. Cooper GS., Parks CG., Treadwell EL., et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002; 11: 161-167. Mavragani CP., Moutsopoulos HM. Lupus nephritis: current issues. Ann Rheum Dis 2003; 62: 795-798 Reveille JD., Bartolucci A., Alarcón GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arhtritis Rheum 1990; 33: 37-48 Bagavant H., Fu SM., Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009; 21: 489-494. Horwitz DA., Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994; 16: 181-200. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85: 303-306. Dean SG., Tyrrell-Price J., Crawley E., et al. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 243-251. Jara LJ., Irigoyen L., Ortiz MJ., et al. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998; 17: 110-114. Foster MH., Kelley VR. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin Nephrol 1999; 19: 173-181. Abbas AK., Lichtman AH., Pillai S. Inmunología celular y molecular. 6ta ed. Barcelona: Elsevier Saunders, 2008. Chan RW., Lai FM., Li EK., et al. Intrarenal cytokine gene expression in lupus Nephritis. Ann Rheum Dis 2007; 66: 886-892 Tucci M., Ciavarella S., Strippoli S., et al. Oversecretion of cytokines and chemokines in lupus nephritis is regulated by intraparenchymal dendritic cells. Ann N. Y. Acad Sci 2009; 1173: 449-457. Akahoshi M., Nakashima H., Tanak Y., et al. Th1/Th2 balnce of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1644-1648. Uhm WS., Na K., Song GW., et al. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003; 42: 935-938. Masutani K., Akahoshi M., Tsuruya K., et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44: 2097-2106. Amit M., Mor A., Weissgarten J., et al. Inactive systemic lupus erytematosus is associated with a normal stimulated Th1/Th2 cytokine secretory pattern. Cytokine 2000; 12: 1405-1408. Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol 2007; 27: 47-58. Betelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235-238. Shimizu S., Sugiyama N., Masutani K., et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL27 receptor (WSX-1). J. Immunol 2005; 175: 7185-7192. Rovin BH., Song H., Birmingham DJ., et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467-473. Rovin BH., Birmingham DJ., Nagaraja HN., et al. Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis 2007; 65: 187-193. Chan RW., Tam LS., Li EK., et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003; 48; 1326-1331. 28. Li Y., Tucci M., Narain S., et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006; 5: 383-388. Appel GB., Silva FG., Pirani CL., et al. Renal involvement in systemic lupus erythematosus: a study of 5 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57: 371- 410. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification or systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725 Bombardier C., Gladman DD., Urowitz MB., et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis study in SLE. Arthritis Rheum. 1992; 35: 630-640. Li Y., Tucci M., Narain S., et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006; 5: 383-388. Gladman DD., Urowitz MB., Kagal A., et al. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 2000; 27: 377-379. Ibañez D., Gladman DD., Urowitz M. Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J. Rheumatol 2007; 34: 336-40. Migliorini P., Anzilotti C., Pratesi F., et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur Cytokine Netw 2010; 21: 264-271. Washburn KK., Zappitelli M., Arikan AA., et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant 2008; 23: 566-572. Tucci M., Lombardi L., Richards HB., et al. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Inmunol 2008; 154: 247-254. 254670 TE05960
url	http://hdl.handle.net/10818/8179
dc.language.iso.es_CO.fl_str_mv	spa
language	spa
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	http://purl.org/coar/access_right/c_abf2
dc.publisher.none.fl_str_mv	Universidad de la Sabana
dc.publisher.program.none.fl_str_mv	Especialización en Medicina Interna
dc.publisher.department.none.fl_str_mv	Facultad de Medicina
publisher.none.fl_str_mv	Universidad de la Sabana
dc.source.none.fl_str_mv	Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana
institution	Universidad de la Sabana
bitstream.url.fl_str_mv	https://intellectum.unisabana.edu.co/bitstream/10818/8179/2/license.txt https://intellectum.unisabana.edu.co/bitstream/10818/8179/5/Ricardo%20Rosero%20%28Carta%29.pdf https://intellectum.unisabana.edu.co/bitstream/10818/8179/3/JUAN%20CAMILO%20RUEDA%20%28T%29%20%281%29FINAL.pdf https://intellectum.unisabana.edu.co/bitstream/10818/8179/4/JUAN%20CAMILO%20RUEDA%20%28T%29%20%281%29FINAL.pdf.txt
bitstream.checksum.fl_str_mv	f52a2cfd4df262e08e9b300d62c85cab a624a265e8c5c787732ffc546928b5f9 f0eab95753063777f3cb4aa4b0d61691 596b932729a448edf40fd1c743281096
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Intellectum Universidad de la Sabana
repository.mail.fl_str_mv	contactointellectum@unisabana.edu.co
_version_	1811952230401572864
spelling	De Zubiría, AlbertoSantander, PaolaRosero Revelo, Ricardo JavierRueda Sánchez, Juan CamiloEspecialista en Medicina Interna2013-07-30T19:56:05Z2013-07-30T19:56:05Z20132013-07-30Singh S., Saxena R., Lupus nephritis. Am J Med Sci 2009; 337: 451-460.Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424.Cervera R., Khamashta MA., Font J., et al. Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. The European Working Party on systemic lupus erithematosus. Medicine (Baltimore) 1993; 72: 113-124Vlachoyiannopoulos PG., Karassa FB., Karakostas KX., et al. Systemic lupus eruthematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993; 2: 303-312.Wallace DJ., Podell TE., Weiner JM., et al. Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 1982; 72: 209-220.Cooper GS., Parks CG., Treadwell EL., et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002; 11: 161-167.Mavragani CP., Moutsopoulos HM. Lupus nephritis: current issues. Ann Rheum Dis 2003; 62: 795-798Reveille JD., Bartolucci A., Alarcón GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arhtritis Rheum 1990; 33: 37-48Bagavant H., Fu SM., Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009; 21: 489-494.Horwitz DA., Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994; 16: 181-200.Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85: 303-306.Dean SG., Tyrrell-Price J., Crawley E., et al. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 243-251.Jara LJ., Irigoyen L., Ortiz MJ., et al. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998; 17: 110-114.Foster MH., Kelley VR. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin Nephrol 1999; 19: 173-181.Abbas AK., Lichtman AH., Pillai S. Inmunología celular y molecular. 6ta ed. Barcelona: Elsevier Saunders, 2008.Chan RW., Lai FM., Li EK., et al. Intrarenal cytokine gene expression in lupus Nephritis. Ann Rheum Dis 2007; 66: 886-892Tucci M., Ciavarella S., Strippoli S., et al. Oversecretion of cytokines and chemokines in lupus nephritis is regulated by intraparenchymal dendritic cells. Ann N. Y. Acad Sci 2009; 1173: 449-457.Akahoshi M., Nakashima H., Tanak Y., et al. Th1/Th2 balnce of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1644-1648.Uhm WS., Na K., Song GW., et al. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003; 42: 935-938.Masutani K., Akahoshi M., Tsuruya K., et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44: 2097-2106.Amit M., Mor A., Weissgarten J., et al. Inactive systemic lupus erytematosus is associated with a normal stimulated Th1/Th2 cytokine secretory pattern. Cytokine 2000; 12: 1405-1408.Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol 2007; 27: 47-58.Betelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235-238.Shimizu S., Sugiyama N., Masutani K., et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL27 receptor (WSX-1). J. Immunol 2005; 175: 7185-7192.Rovin BH., Song H., Birmingham DJ., et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467-473.Rovin BH., Birmingham DJ., Nagaraja HN., et al. Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis 2007; 65: 187-193.Chan RW., Tam LS., Li EK., et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003; 48; 1326-1331. 28. Li Y., Tucci M., Narain S., et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006; 5: 383-388.Appel GB., Silva FG., Pirani CL., et al. Renal involvement in systemic lupus erythematosus: a study of 5 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57: 371- 410.Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification or systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725Bombardier C., Gladman DD., Urowitz MB., et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis study in SLE. Arthritis Rheum. 1992; 35: 630-640.Li Y., Tucci M., Narain S., et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006; 5: 383-388.Gladman DD., Urowitz MB., Kagal A., et al. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 2000; 27: 377-379.Ibañez D., Gladman DD., Urowitz M. Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J. Rheumatol 2007; 34: 336-40.Migliorini P., Anzilotti C., Pratesi F., et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur Cytokine Netw 2010; 21: 264-271.Washburn KK., Zappitelli M., Arikan AA., et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant 2008; 23: 566-572.Tucci M., Lombardi L., Richards HB., et al. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Inmunol 2008; 154: 247-254.http://hdl.handle.net/10818/8179254670TE0596072 Páginas.Los estudios han sugerido que hay un imbalance en la producción de células T helper, (Th1 y Th2) que juega un papel importante en la patogénesis del LES. Además, se ha demostrado el predominio de genes de expresión de las citocinas Th1 y MCP-1 en el sedimento urinario de pacientes con nefritis lupica activa. Se realizó un análisis cuantitativo de las citocinas pro Th-1 (IL-18) y MCP-1 en sedimento urinario de pacientes con LES. Nuestros resultados confirman observaciones previamente mencionadas, donde hubo elevación de los niveles de MCP-1 en sedimento urinario en pacientes con nefritis lupica, además esta es la primera vez que se medió las citocinas pro Th1 (IL-18) en orina, encontrando elevación en este mismo grupo de pacientes.spaUniversidad de la SabanaEspecialización en Medicina InternaFacultad de MedicinaUniversidad de La SabanaIntellectum Repositorio Universidad de La SabanaLupus eritematoso sistémicoCitocinasNefritisNiveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémicobachelorThesisTesis de especializaciónpublishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/access_right/c_abf2LICENSElicense.txtlicense.txttext/plain; charset=utf-8498https://intellectum.unisabana.edu.co/bitstream/10818/8179/2/license.txtf52a2cfd4df262e08e9b300d62c85cabMD52Ricardo Rosero (Carta).pdfRicardo Rosero (Carta).pdfapplication/pdf1063201https://intellectum.unisabana.edu.co/bitstream/10818/8179/5/Ricardo%20Rosero%20%28Carta%29.pdfa624a265e8c5c787732ffc546928b5f9MD55ORIGINALJUAN CAMILO RUEDA (T) (1)FINAL.pdfJUAN CAMILO RUEDA (T) (1)FINAL.pdfVer documento en PDFapplication/pdf2531747https://intellectum.unisabana.edu.co/bitstream/10818/8179/3/JUAN%20CAMILO%20RUEDA%20%28T%29%20%281%29FINAL.pdff0eab95753063777f3cb4aa4b0d61691MD53TEXTJUAN CAMILO RUEDA (T) (1)FINAL.pdf.txtJUAN CAMILO RUEDA (T) (1)FINAL.pdf.txtExtracted Texttext/plain74https://intellectum.unisabana.edu.co/bitstream/10818/8179/4/JUAN%20CAMILO%20RUEDA%20%28T%29%20%281%29FINAL.pdf.txt596b932729a448edf40fd1c743281096MD5410818/8179oai:intellectum.unisabana.edu.co:10818/81792019-08-13 15:21:48.333Intellectum Universidad de la Sabanacontactointellectum@unisabana.edu.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

Niveles de citocinas pro Th1 en orina de pacientes con lupus eritematoso sistémico

Publicaciones similares